Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children

Pfizer

Status and phase

Completed

Phase 3

Conditions

Encephalitis, Tick-Borne

Treatments

Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00840801

2008-002691-10 (EudraCT Number)

700801

B9371022 (Other Identifier)

EUDRACT NUMBER: 2008-002691-10

Details and patient eligibility

About

The objective of this study is to assess the immunogenicity, safety and interchangeability of two different TBE vaccines in children aged 1-11 years, the first and second vaccination with either FSME-IMMUN 0.25ml Junior or Encepur 0.25ml Children and the third vaccination with FSME-IMMUN 0.25 ml Junior only, administered according to the conventional schedule (0, 28 and 360 days).

Enrollment

302 patients

Sex

All

Ages

1 to 11 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male and female children will be eligible for participation in this study if:

they are aged >= 1 years (from the 1st birthday) to 11 years (to the last day before the 12th birthday) at screening;
their parents / legal guardians provide written informed consent;
children provide written assent to the study according to age and capacity of understanding;
their parents/guardians understand the nature of the clinical study and will comply with the requirements of the protocol (e.g., completion of the Subject Diary, return for follow-up visits);
they are generally healthy, (i.e. the physician would have no reservations vaccinating with a TBE vaccine outside the scope of a clinical study);
provide a negative pregnancy test result at the first medical examination (if the subject is a female and capable of bearing children).

Exclusion criteria

Subjects will be excluded from participation if:

they have a history of any previous TBE vaccination;
they have a history of TBE infection;
they have a history of infection with other flaviviruses;
they have a history of vaccination against yellow fever and/or Japanese B encephalitis;
they have a history of severe allergic reactions, in particular a known sensitivity or allergy to any components of the vaccines;
they are suffering from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions;
they have received any blood product or immunoglobulins within 90 days prior to study entry;
they are known to be Human Immunodeficiency Virus (HIV) positive (an HIV test is not required specifically for the purpose of this study);
they have a functional or surgical asplenia;
they have a rash or other dermatological condition at the injection site which could interfere with injection site reaction evaluation;
they were administered an investigational product within six weeks prior to study start or are concurrently participating in another clinical study that includes the administration of an investigational product;
they are pregnant or breastfeeding (if a female subject);
they or their parents/legal guardian(s) are in a dependent relationship with the study investigator or with a study team member. Dependent relationship includes close relatives (i.e., children or grandchildren, partner/spouse, siblings) as well as employees of the investigator or site conducting the study.
Subjects who have an acute illness with or without elevated body temperature (>=37.5°C) within 3 days prior to the scheduled first vaccination will not be vaccinated. Subjects may be included at a repeat visit provided that (1) the illness has resolved (body temperature < 37.5 °C), (2) the repeat visit is no more than 14 calendar days after the Screening Visit, and (3) the center is still open for recruitment.
If subjects have received antipyretics within 4 hours prior to the scheduled time of vaccination, the vaccination should be performed at a later date, as long as the center is still open for recruitment.
Subjects who received any live vaccine within 4 weeks or any inactivated vaccine within 2 weeks prior to the scheduled first study vaccination will not be vaccinated until an interval of 4 or 2 weeks, respectively, has passed, provided the center is still open for recruitment.
If a subject was bitten by a tick within 4 weeks prior to the scheduled first or second vaccination, the vaccination must be postponed until an interval of 4 weeks has passed.